UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

September 22, 2022

Date of Report (date of earliest event reported)

LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

22-2343568

(I.R.S. Employer Identification No.)

110 Allen Road, Second Floor, Basking Ridge, NJ 07920 (Address of Principal Executive Offices)(ZipCode) (908) 842-0100

Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	LSTA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

A copy of a slide presentation that Lisata Therapeutics, Inc. (the "Company") will use at investor and industry conferences and presentations is attached to this Current Report as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

Item 8.01 Other Events

As previously disclosed, in December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA®, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with Coronary Microvascular Dysfunction (CMD) and without obstructive coronary artery disease and was expected to complete enrollment approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the COVID-19 pandemic resulted in insurmountable enrollment are challenges and population heterogenicity. As a result, in May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA® in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders' input, the Company's board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo alone without a strategic partner. Accordingly, the Company's board of directors concluded that XOWNA® development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.

Item 9.01 Exhibits.

Exhibit No. Description

99.1 Lisata Therapeutics, Inc. Corporate Presentation, September 22, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CALADRIUS BIOSCIENCES, INC.

By: <u>/s/ David J. Mazzo</u> Name: David J. Mazzo, PhD Title: Chief Executive Officer

Dated: September 22, 2022



Forward-looking Statements

This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this communication, the words "may," "could," "should," "anticipate," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements relating to the long-term success of Lisata's recently completed merger (the "Merger") with Cend Therapeutics, Inc. ("Cend"), including the ongoing integration of Cend's operations; Lisata's continued listing on the Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of Lisata; the approach Lisata is taking to discover and develop novel therapeutics; the adequacy of Lisata's capital to support its future operations and its ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of Lisata's product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ongoing COVID-19 pandemic on Lisata's business, the safety and efficacy of Lisata's product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata's clinical programs, Lisata's ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata's scientific studies, Lisata's ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata's markets, the ability of Lisata to protect its intellectual property rights; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; potential underperformance of Lisata's business following the Merger as compared to management's initial expectations; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata's Annual Report on Form 10-K filed with the SEC on March 22, 2022, and in the proxy statement/prospectus filed by Lisata with the Securities and Exchange Commission relating to the Merger. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

LISATAY 2

Investment highlights

NOVEL INTRATUMORAL DELIVERY TECHNOLOGY TO IMPROVE THERAPEUTIC EFFICACY OF SoC* DRUGS | EXISTING CAPITAL EXPECTED TO FUND ANTICIPATED MILESTONES | EXISTING STRATEGIC PARTNERSHIPS



Nasdaq-listed with a focused mid-late-stage clinical development pipeline and a promising preclinical platform



Stable finances: ~\$76 million cash & investments as of 9/15/22; no debt



Proprietary field-leading technology in underserved global indications backed by a strong IP portfolio



Platform technology "validated" by strong existing partnerships with potential for many others



Multiple potential value creating data and business development events projected in the next 12-24 months



Seasoned management with domain expertise along with big pharma and emerging pharma experience

*SoC = standard-of-care

LISATA

0, 00,

Proprietary platform technologies



CendR Platform™ - a targeted tissue penetration technology to enhance drug delivery to solid tumors

- Converts tumor stroma from barrier to conduit for efficient delivery of chemo-, targeted and immunotherapies
 - · Delivery accomplished via co-administration or by tethering
- · Selectively depletes intratumoral immunosuppressive cells
- · Combination with many existing chemo- and immuno-therapeutics possible in a variety of indications



Tumor-Penetrating Nanocomplex (TPN) Platform™ - broad potential for delivery of nucleic acid-based therapies

- Designed to address challenges to ASO and siRNA delivery posed by stroma barrier and endosome sequestration
- Clinical development candidate identification expected in 2023



CD34+ Cell Therapy Platform - designed to address diseases and conditions caused by ischemia

- CD34+ cells repeatedly demonstrated vascular repair in multiple organs and have been clinically studied in a variety of ischemic diseases by numerous investigators across many sites and countries
 - Consistent results of rigorous clinical studies comprising >1,000 patients published in peer reviewed journals^{1.4}
 - Single treatments elicited durable therapeutic effects
 - · Treatment generally well-tolerated

¹ Povsic, T. et al. JACC Cardiovasc Interv, 2016, 9 (15) 1576-

³ Velagapudi P, et al, Cardiovas Revasc Med, 2018, 20(3):215-2: ⁴ Henry T.D., et al, European Heart Jour 2018, 2208-2216

LISATA

Clinical development pipeline with broad therapeutic reach



LSTA1 (formerly known as CEND-1), advancing in a variety of difficult-to-treat solid tumor applications

- Ongoing multiple studies in first-line, metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with standard-of-care (SoC) chemotherapy
- Basket trial initiation planned in 2023 expanding development to other solid tumors and additional anti-cancer drug combinations, including immunotherapies
- Granted Fast Track as well as Orphan Drug Designation by the U.S. FDA in PDAC



CD34+ autologous cell therapy development programs advancing to next development milestone

- XOWNA® development will continue if a partner is identified that can contribute the necessary capital
- HONEDRA® (SAKIGAKE designated) advancing through Japanese regulatory process toward JNDA
- CLBS201 proof-of-concept (PoC) results expected in 1Q23
- No additional capital outlay necessary to reach identified milestones

LISATA

Therapeutic potential attracts strategic partners



Strategic partnership in China with Qilu Pharmaceutical

- Exclusive rights to LSTA1 in China, Taiwan, Hong Kong and Macau
- Qilu assumes all development and commercialization responsibilities in the licensed territories
- Potential for up to \$225 million to Lisata for milestones and tiered double-digit royalties on potential sales
- \$10 million payment due to Lisata for proceeding to Phase 3 in mPDAC in China



Clinical development collaboration with Roche in mPDAC

LSTA1 tested in combination with atezolizumab in mPDAC as part of Morpheus trial



Additional partnership opportunities for broad applications of LSTA1 and the CendR Platform™



Ongoing discussions support goal to partner CD34+ programs

LISATA

Robust portfolio of development candidates


Sponsor/Funding Partner	Trial Products	Indication	Development Stage	Next Development Milestone
		CendR Platform™ Programs		
Lisata (Global)	Gemcitabine/nab-paclitaxel ± LSTA1	First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Phase 2/3 adaptive	FDA feedback 4Q22 Trial initiation planned 1Q/2Q23
AGITG (Australia/New Zealand)	Gemcitabine/nab-paclitaxel ± LSTA1		Phase 2b (ASCEND)	Enrollment completion target 4Q2: Data expected 2024
Qilu (China)	Gemcitabine/nab-paclitaxel ± LSTA1		Phase 1b/2	Preliminary data expected 2H23
Roche/Lisata (Multi-national)	LSTA1 + nab-paclitaxel + gemcitabine ± atezolizumab		Phase 1b/2	Trial initiation target 1Q23
KUCC - IIT (U.S.)	LSTA1 + FOLFIRINOX + panitumumab*	Pancreatic, Colon and Appendiceal Cancers	Phase 1b/2 (CENDIFOX)	Enrollment completion target 4Q23 Data expected 2024
Lisata (U.S.)	LSTA1 in combination with SoC	Various Solid Tumors	Phase 2a	Trial initiation planned 1Q/2Q23
Lisata (U.S.)	TPN development candidate		Preclinical	Development candidate ID target 202 Phase 1 planned for 2024
		CD34+ Platform Programs		
Lisata (U.S.)	XOWNA® (LSTA16)	Coronary Microvascular Dysfunction	Phase 2b (FREEDOM)	Partner sought to advance development
Lisata (Japan)	HONEDRA® (LSTA12)	Critical Limb Ischemia and Buerger's Disease	Phase 2	PMDA consultation underway
Lisata (U.S.)	LSTA201	Diabetic Kidney Disease	Phase 1b - PoC	Data expected 1Q23

Panitumumab may be added for colorectal or appendiceal patients without Ras mutation


LISATA




LSTA1 mechanism of action (part 1)



LSTA1 mechanism of action (part 2)




LSTA1 selectively and efficiently facilitates intratumoral delivery



¹ Braun et al., Nature Mater. 2014. ² Liu. Braun et al., Nature Comm. 2017.

LISATA

Increased tumor penetration enhances activity across treatment modalities



SATA♥ 12


Treatment of solid tumors represents a large unmet clinical need


12,810

10,100

8,550

7,570 287,270





Ovary Uterine corpus

Liver & intrahepatic bile duct

Brain & other nervous system

Leukemia Non-Hodgkin lymphoma

ne: 72, Issue: 1, Pages: 7-33, First published: 12 January 2022, DOI: (10.3322/caac.21708)

1196

6% 4% 4%

34,500

28,400 25,970

20,420

13,250

12,120 11,700

10,710

Prostate

Colon & rectum Pancreas

Esophagus

Liver & intrahepatic bile duct

Non-Hodgkin lymphoma

Brain & other nervous system

It is estimated that more than 1.9 million new cases of cancer will be diagnosed in 2022

In the U.S. alone, over 90% of new cancer cases are solid tumors

An estimated 609,360 people will die from cancer in 2022, corresponding to ~1,700 deaths per day

Pancreatic cancer is one of the deadliest cancers in the U.S. with a five-year survival rate of only 11%, representing a high unmet medical need

LISATA

Compelling Phase 1 clinical results of LSTA1

- Phase 1b: 31 subjects enrolled, 29 evaluable first-line, mPDAC patients from 3 sites in Australia [gemcitabine + nab-paclitaxel) with and without LSTA1
 - LSTA1 well-tolerated, no dose-limiting toxicities; safety with LSTA1 consistent with SoC alone
 - Favorable LSTA1 pharmacokinetic profile with median $T_{1/2}$ ~2 hours
 - Unprecedented improvement of SoC anti-tumor activity 1,2
 - Overall Response Rate (PR+CR=ORR) 59% (vs. 23%) including Complete Response
 - Disease Control Rate at 16 weeks 79.3% (vs. 48%)
 - CA19-9 circulating tumor biomarker reductions in 96% of patients (vs. 61%)
 - Median Progression-Free Survival 9.7 months (vs. 5.5 months)
 - Median Overall Survival 13.2 months (vs. 8.5 months)

Dean A, et al., The Lancet Gastroenterology & Hepatology, 2022 Von Hoff D, et al., New England Journal of Medicine, 2013.

LISATA

Ongoing & Planned LSTA1 Clinical Trials

ASCEND: Phase 2b randomized, double-blind trial in Aus and NZ

Sponsor/Partner	 Australasian Gastro-Intestinal Trials Group (AGITG) in collaboration with the NHMRC Clinical To Centre at the University of Sydney AGITG co-funded 	rial
Design	 Phase 2b randomized, double-blind study in mPDAC 	
Study Size	■ 125 subjects (~40 sites in Australia and New Zealand)	
Endpoints	 Primary: Progression Free Survival Secondary: AEs, SAEs, Overall Survival, Objective Tumor Response Rate 	
Control/Comparator	 SoC chemotherapy (gemcitabine/nab-paclitaxel) with LSTA1 or placebo 	
Objective	 Evaluate the effect of adding LSTA1, compared to placebo, to SoC chemotherapy in patients with untreated mPDAC 	
Timing	Enrollment completion target 4Q23Data expected 2024	
LISATA		16

LSTA1 Phase 1b/2 trial in China


Sponsor/Partner	QILU Pharmaceutical (provides all funding)
Design	 Phase 1b/2 open-label study in advanced mPDAC patients
Study Size	■ 50 subjects (~15 sites; Chinese population)
Endpoints	 Primary: AEs, SAEs, Objective Response Rate, Duration Response Rate, Disease Control Rate, Overall Survival, and Progression Free Survival Secondary: Pharmacokinetic parameters
Control/Comparator	SoC chemotherapy (gemcitabine/Qilu-produced nab-paclitaxel) with and without LSTA1
Objective	 Evaluate safety, pharmacokinetics and preliminary efficacy of LSTA1 added to SoC in Chinese patients with mPDAC
Timing	 Preliminary data expected 1H23; full data expected 2024
LISATA	17

CENDIFOX: Phase 1b/2 trial in U.S.

Sponsor/Partner	 University of Kansas Medical Center (Investigator initiated trial)
Design	 Phase 1b/2 open-label study in pancreatic, colon and appendiceal cancers
Study Size	50 subjects
Endpoints	 Primary: Drug Safety Secondary: Overall Survival, Disease-free Survival, Overall Response Rate, RO Resection Rate, Pathological Response Rate
Control/Comparator	SoC chemotherapy (neoadjuvant FOLFIRINOX-based therapies with LSTA1 or placebo
Objective	 Evaluate the safety of LSTA1 in combination with neoadjuvant FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers
Timing	Enrollment completion target 4Q23Data expected 2024
LISATA	18

Planned LSTA1 clinical trials

	PHASE 2/3 ADAPTIVE TRIAL IN mPDAC	PHASE 2A BASKET TRIAL IN MULTIPLE TUMOR TYPES
Sponsor	Lisata	Lisata
Design	 Phase 2/3, adaptive, double-blind, placebo- controlled, randomized trial in mPDAC (Global) - pending FDA agreement 	 Phase 2, double-blind, placebo-controlled trial in multiple advanced solid tumor types (U.S.)
Study Size	■ N=389	■ N=120 (depending on number of arms in the "basket")
Endpoints	Primary: OSSecondary: Safety, ORR, PFS	Primary: OSSecondary: Safety, ORR, PFS
Control/Comparator	 Placebo; in combination with SoC chemo (gem/nab-paclitaxel) 	 Placebo; in combination with tumor-type specific SoC chemo
Objective	 Evaluate the efficacy and safety of LSTA1 in subjects with previously untreated mPDAC (next step in development toward U.S. registration) 	 Evaluate the preliminary efficacy, safety and tolerability of LSTA1 in combination with standards of care in subjects with advanced solid tumors
Timing	FDA feedback: 4Q22Trial initiation target: 1Q/2Q23	Trial initiation target: 1Q/2Q23



TPN Platform[™] for nucleic acid medicine delivery in solid tumors


DELIVERY ISSUES LIMIT ANTICANCER APPLICATIONS OF RNA-BASED THERAPEUTICS

- RNA-based drugs have not been successful in the treatment of cancer despite advancement of candidates to multiple "undruggable" high-interest anticancer targets
- Early antisense oligonucleotide (ASO) and small interfering RNA (siRNA) anticancer programs failed to translate preclinical efficacy to clinical success
 - >95% of ASO and siRNA drugs sequestered in endosomes
 - Tumor stroma serves as primary impediment to effective delivery
 - High doses to drive intratumoral concentration resulted in on- and off-target side effects, including, but not limited to, clotting factors and renal toxicities
- Passive targeting (i.e., lipid nanoparticles) appears ineffective
- Non-targeted cell-/tissue-penetrating moieties can disrupt unintended tissues
- Moieties to target tumor increase bulk and may exacerbate problem of transiting stroma

Targeted approach to transit tumor stroma may enable effective solid tumor treatment

ISATA 21

TPN Platform[™] addresses nucleic acid tumor delivery challenges



- Peptides provide tumor and/or immune cell targeting
- Unique CendR pathway activation to penetrate stroma and deliver efficacious drug concentrations to all layers of solid tumors
- Technologies to evade endosome sequestration
- Targeted tissue penetration drives dose- and toxicity-sparing potency
- Ease of synthesis vs. biologics such as virus-like particles, Ab-conjugates or exosomes

ISAIA 22





XOWNA® development status

Summary

- Coronary Microvascular Dysfunction (CMD) represents a large unmet medical need
 - Deficient heart microvasculature without large vessel obstructive disease causing frequent, severe angina
 - · Not treatable by stents/bypass; responds poorly or not at all to available pharmacotherapies
 - U.S. CMD population potentially treatable by XOWNA® ranges from ~415,000 to ~1.6 million patients¹
 - Compelling Phase 2a (published ESCaPE-CMD trial) results show the potential of XOWNA® to significantly improve symptoms of CMD
 - Phase 2b (FREEDOM) trial impacted directly and indirectly by COVID pandemic resulted in insurmountable enrollment rate
 challenges and population heterogenicity; trial enrollment suspended in May 2022 after ~1/3 of the intended subjects enrolled

Next Steps

- Analysis of results of FREEDOM Trial subjects completing 6-month follow-up along with KOL input suggests that execution of a redesigned FREEDOM-like trial is an appropriate next step
 - · Cost of such trial is financially challenging in a "go-it-alone" strategy
- XOWNA® development will continue if a partner is identified that can contribute the necessary capital

¹ Marinescu MA, et al. JACC Cardiovasc Imaging. 2015;8:210-220

LISATAY

0.5



Indication: critical limb ischemia (CLI)

- Severe arterial obstruction impeding blood flow in the lower extremities
 - · Includes severe rest pain and non-healing ulcers
- Buerger's disease (BD: inflammation in small and medium arteries) is a form of CLI associated with a history of heavy smoking (orphan population)
- Patients with no-option CLI have persistent symptoms even after bypass surgery, angioplasty, stenting and available pharmacotherapy
- CLI has been categorized as Rutherford Classification Stages¹
 - Stages: 1-3 (mild to severe claudication); 4 (rest pain); 5 (minor tissue loss); 6 (major tissue loss)
 - CLI patients are at high risk of amputation and death with increasing Rutherford score
- Multi-million-dollar opportunity with an increasing prevalence of arteriosclerosis obliterans (ASO) and CLI in Japan
- Positive previously published Phase 2 results in Japan^{3,4}

Reinecke H., European Heart Journal, 2015 Apr 14;36(15):932-8 Kinoshita et al, Atherosclerosis 224 (2012) 440-445

Losordo, D.W. et al, Circulation 2012; 5(6)

LISATA

HONEDRA® registration-eligible study in Japan


Primary Endpoint	Time to continuous CLI-free (2 consecutive monthly visits, adjudicated independently)
Target Study Size	 35 subjects; recruited across 12 centers in Japan 30 with no-option CLI (ASO) + 5 with BD; all Rutherford category 4 or 5
Dose	■ Up to 10 ⁶ cells/kg of HONEDRA® (LSTA12)
Control/Comparator	 SoC: wound care plus drugs approved in Japan Including antimicrobials, antiplatelets, anticoagulants and vasodilators
Mode of Administration	 Intramuscular, 20 injections in affected lower limb in a single treatment
Objective	 Demonstrate a trend toward efficacy and acceptable safety to qualify for consideration of early conditional approval under Japan's Regenerative Medicine Development Guidelines

ISATA 28

HONEDRA® development next steps

- Combined CLI and BD interim data suggest trend toward efficacy and acceptable safety
 - HONEDRA® was safe and well tolerated
 - Treatment group reached CLI-free status faster than SoC group (primary endpoint)
- Consultation process with the Pharmaceuticals & Medical Devices Agency (PDMA) is underway in support of the planned filing of a Japan New Drug Application

LISATAY 29



LSTA201 in diabetic kidney disease (DKD)

Development Rationale

- The stages of CKD are determined by GFR rate, an indication of how well the kidneys are filtering blood¹
- CKD is often associated with progressive microvasculature damage and loss^{2,3}
- Preclinical studies show that microcirculation replenishment improves kidney function
- CD34+ cells are promoters of new capillary growth, improving the microvasculature
- Therapies currently available and/or expected to be available over the next 5-10 years will slow the progression of CKD/DKD
- A regenerative DKD therapy (i.e., one that reverses disease course) could represent a medical and pharmacoeconomic breakthrough

Clinical Strategy

- To demonstrate that CD34+ cell mobilization, donation, and administration can be tolerated by patients with CKD and type 2 diabetes
- To demonstrate that regeneration of the kidney microcirculation using CD34+ cell therapy improves kidney function

2020 Dallas Nephrology Associates


2020 Dallas Rephrology Associates.
 2 Chade AR. (2017) Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury. Hypertension: 69(4):551-56

ISATA

LSTA201: Phase 1b open-label, proof-of-concept study in U.S.

Endpoints	 Change in eGFR compared to baseline, assessed at 6 months Change in Urine albumin-to-creatinine ratio (UACR) and urine protein-to-creatinine ratio (UPCR) from baseline to 3 and 6 months 	
Study Size	• 6 patients (1 sentinel - unilateral inj., 1 sentinel - bilateral inj., 4 bilateral inj. patients)	
Dose	■ 1 x 10 ⁶ - 300 x 10 ⁶ cells administered as a one-time infusion	
Patient Population	Stage 3b DKD	
Design	Open-label, proof-of-concept Phase 1b study	
Mode of Administration	 Intra-arterial injection into one or both renal arteries 	
Timing	 Top-line data target for all subjects: 1Q23 	
LISATA		32

Anticipated milestones



Investment highlights

NOVEL INTRATUMORAL DELIVERY TECHNOLOGY TO IMPROVE THERAPEUTIC EFFICACY OF SoC* DRUGS | EXISTING CAPITAL EXPECTED TO FUND ANTICIPATED MILESTONES | EXISTING STRATEGIC PARTNERSHIPS



Nasdaq-listed with a focused mid-late-stage clinical development pipeline and a promising preclinical platform



Stable finances: ~\$76 million cash & investments as of 9/15/22; no debt



Proprietary field-leading technology in underserved global indications backed by a strong IP portfolio



Platform technology "validated" by strong existing partnerships with potential for many others



Multiple potential value creating data and business development events projected in the next 12-24 months



Seasoned management with domain expertise along with big pharma and emerging pharma experience

*SoC = standard-of-care

LISATA

.

